Alcon Takes $402M Non-Cash Charge After PowerVision IOL Shutdown
Alcon discontinued the intraocular lens programs acquired in its 2019 PowerVision purchase after clinical study data showed persistent unpredictable post-surgical visual outcomes in a subset of patients. The company recorded a $402 million pre-tax non-cash charge in Q2 2026 without affecting cash or changing long-range objectives. Reported operating income fell 96%, though core profitability and sales rose as other portfolio launches continued to drive growth.